Viking Therapeutics favored over Dyne Therapeutics for 2026 healthcare investment

Industry
โดย The Motley Fool·Read original
Summary · why it matters

The Motley Fool selects Viking Therapeutics over Dyne Therapeutics as the better healthcare stock for 2026, citing the massive obesity-treatment market opportunity for Viking's weight-loss candidate VK2735. Both clinical-stage biotechs reported zero revenue and widening net losses in fiscal 2025, with Dyne posting a loss of nearly $446.2 million and Viking close to $359.6 million. Viking carries no debt and holds a current ratio of roughly 9.3x, while Dyne has a debt-to-equity ratio of 0.19x and a current ratio of approximately 22.3x. The analysis notes Dyne's focus on rare neuromuscular diseases limits its market size, whereas Viking's phase 3 obesity program targets a far larger patient population despite competition from Eli Lilly and Novo Nordisk. Viking also faces an investigation into potential securities-law violations and relies on a license agreement with Ligand Pharmaceuticals.

Impact on stocks 5

Biotech & Genomic Medicine± Mixed · 5 stocks
Viking Therapeutics Inc
VKTX
▲ PositiveDemandrelevance

The Motley Fool selects Viking as the better healthcare stock for 2026, citing its massive obesity-treatment market opportunity for VK2735.

Dyne Therapeutics Inc
DYN
▼ NegativeCompetitionrelevance

The Motley Fool selects Viking over Dyne, citing Dyne's focus on rare neuromuscular diseases limits its market size compared to Viking's obesity program.

© 2026 MarketDXNews